rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 750 participants.

Also called NCT07606807

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 750 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07606807
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07606807. Randomized; single masking; primary purpose treatment. Start 2026-08-01 (anticipated); primary completion 2028-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window
Acronym
SIMPLIFIED
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
Intervention (Drug)
Standard medical treatment
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct07606807
Content hash
9fe74d78d22ee817800f22e8b01337b8c4a380e70531ef408f582aeaf2872886